No Data
No Data
China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.
In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
JILIN CHANGLONG (08049) subscribes to 20 million yuan financial products.
JILIN CHANGLONG (08049) announced that on December 27, 2024, the company will recognize to the Industrial And Commercial Bank Of China...
Express News | Jilin Province Huinan Changlong Bio-Pharmacy - Subscribed for Wealth Management Product From Industrial and Commercial Bank of China for RMB20 Mln
No Data